Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the Listing Regulations, we would like to inform you that the management of Neogen Chemicals Limited will be participating in "B&K Securities Annual Flagship Conference - Trinity India 2023" at Hotel Trident BKC, Mumbai on Thursday, June 1, 2023. Neogen Chemicals Ltd - 542665 - Compliances-Reg.24(A)-Annual Secretarial Compliance
In terms of Regulation 24A of the Listing Regulations, we enclose herewith the Annual Secretarial Compliance Report duly issued by DVD & Associates, Company Secretaries for the financial year ended March 31, 2023. Kindly take the same on your records. Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
With reference to the captioned subject, please find enclosed herewith the Earnings Call Transcript of the Company's Q4 FY23 Earnings Conference Call held on May 15, 2023. Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
In compliance with Regulation 30 of the Listing Regulations, the audio recording of the earnings conference call held on Monday, May 15, 2023 for analysts and investors to discuss the Q4 FY23 results, is hosted on Company''s website at https://neogenchem.com/wp-content/uploads/Neogen-Chemicals-Q4-FY23-Earnings-Conference-Call-Audio.mp3 .
Neogen Chemicals Results Earnings Call for Q4FY23
Conference Call with Neogen Chemicals Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript. FY23 Annual Result Announced for Neogen Chemicals Ltd.
Specialty Chemicals company Neogen Chemicals announced FY23 results: In FY23, revenues were at Rs 686.2 crore, with a growth of 41% YoY EBITDA at Rs 111.6 crore in FY23 was higher by 29% on account of a positive mix change in the business Profit after tax (PAT) stood at Rs 50.0 crore during FY23, higher by 12% compared to Rs 44.6 crore in FY22 Earnings per share (EPS) for FY23 stood at Rs 20.03 per share (Rs. 18.70 per share in FY22) The Board has recommended a final dividend of Rs 3 per equity share for FY23 (Rs. 2.75 per equity share in FY22) subject to the approval of the shareholders Collective CAPEX for all the new projects is ~Rs 450 crore Debt to Equity will continue to remain below 1.25x Commenting on the Q4FY23 & FY23 performance, Haridas Kanani, Chairman & Managing Director, Neogen Chemicals said: “I am happy to share that we have concluded the year on a strong note despite challenging operating scenario aggravated by continued volatility in input costs, disruption of global supply chains due to Russia Ukraine conflict and variations in foreign exchange rates among others. Amid all these headwinds, we demonstrated solid financial performance in FY23 steered by 41% growth in revenues and 29% expansion in EBITDA. More importantly, we reported the Highest-Ever revenues and PAT in the Company’s history propelled by a positive demand environment, the onset of several expansion initiatives, and the augmentation of the product portfolio. This is a testament of our commitment and perseverance towards building a solid foundation for the future. FY23 was a momentous year for Neogen Chemicals as we charted ambitious growth plans for both existing as well as Battery Chemicals business and saw a lot of these initiatives take concrete shape. On one hand, we acquired 100% stake in BuLi Chemicals India Private Limited (“Buli Chem”) to strengthen our product offerings while on the other hand, we signed a landmark agreement with MUIS, Japan to acquire a manufacturing technology license for electrolytes in India. Both these events will significantly bolster our competitive position in the market and lay the roadmap for the future. We have markedly expanded our R&D; prowess across several high-potential chemistries to offer deep value to our customers. Initiatives under the Battery Chemicals business are progressing well, and we are on track to achieve several milestones as per our internal forecasts. The roadmap appears equally encouraging and we are ready to march to the next leg of growth that will demonstrate our manufacturing capabilities at scale as well as expertise in several complex chemistries. The industry is supportive, and the demand scenario continues to be favourable. Our objective is to continue on this profitable growth journey and deliver sustained value for our stakeholders.” Result PDF
Neogen Chem plunges 5% on disappointing quarterly performance
Neogen Chemicals also has a slew of capacity expansion plans under the pipeline, with an estimated cost of around Rs 450 crore. Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, please find enclosed herewith the Press Release on the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2023. The Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2023 and the Press Release are also being uploaded on the Company's website at https://neogenchem.com/financial-performance/ . Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Investor Presentation
With reference to the captioned subject, please find enclosed herewith the Earnings Presentation on the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2023. The Audited Financial Results for the quarter and year ended March 31, 2023 and the Earnings Presentation are also being uploaded on the Company's website at https://neogenchem.com/financial-performance/ Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Dividend Updates
1. Approved the Audited Financial Results (Standalone and Consolidated) of the Company along with the Audit Reports for the Quarter and Financial Year ended March 31, 2023, pursuant to Regulation 33 of the Listing Regulations, which has been duly reviewed and recommended by the Audit Committee; Pursuant to Regulation 33(3) (d) of the Listing Regulations, we would like to declare that the Statutory Auditors of the Company M/s. JMT & Associates, Chartered Accountants (FRN: 104167W) have issued the Auditors Report on Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Financial Year ended March 31, 2023 with un-modified opinion and a declaration to that effect is enclosed. 2. Recommended a final dividend of Rs. 3 per Equity Share for the Financial Year 2022-23, subject to approval of shareholders at the ensuing Annual General Meeting of the Company.